Barrow Hanley Mewhinney & Strauss LLC Lowers Holdings in Sanofi $SNY

Barrow Hanley Mewhinney & Strauss LLC lowered its position in Sanofi (NASDAQ:SNY) by 2.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,126,993 shares of the company’s stock after selling 153,543 shares during the quarter. Barrow Hanley Mewhinney & Strauss LLC owned approximately 0.29% of Sanofi worth $336,394,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of SNY. Brighton Jones LLC increased its stake in shares of Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after buying an additional 1,869 shares during the period. AQR Capital Management LLC grew its holdings in Sanofi by 107.2% during the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after acquiring an additional 15,791 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Sanofi by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after purchasing an additional 752 shares during the period. Sivia Capital Partners LLC raised its holdings in shares of Sanofi by 5.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after purchasing an additional 347 shares in the last quarter. Finally, Savant Capital LLC raised its holdings in shares of Sanofi by 17.1% in the 2nd quarter. Savant Capital LLC now owns 8,423 shares of the company’s stock valued at $407,000 after purchasing an additional 1,227 shares in the last quarter. 14.03% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

SNY has been the topic of a number of recent research reports. TD Cowen reiterated a “hold” rating on shares of Sanofi in a research note on Tuesday, December 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a research report on Friday, January 16th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. Finally, UBS Group reiterated a “neutral” rating on shares of Sanofi in a research note on Friday, January 16th. Five investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $62.67.

Sanofi Stock Performance

Shares of Sanofi stock opened at $43.97 on Wednesday. The company has a 50 day moving average price of $47.13 and a 200 day moving average price of $48.35. The firm has a market capitalization of $107.24 billion, a P/E ratio of 12.21, a PEG ratio of 1.14 and a beta of 0.45. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. Sanofi has a 52 week low of $43.34 and a 52 week high of $59.88.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.